Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs

Autor:	Lucile Gioda, Andrea García de Salazar Alcalá, Frederic Beugnet, Alia Dehman
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	Firocoxib medicine.medical_specialty Acute arthritis 040301 veterinary sciences Lameness Animal Untreated group Arthritis Osteoarthritis Force-plate Gastroenterology 0403 veterinary science Random Allocation 03 medical and health sciences chemistry.chemical_compound Dogs 4-Butyrolactone Internal medicine medicine Dog Animals Potency Dog Diseases Sulfones 030304 developmental biology 0303 health sciences lcsh:Veterinary medicine General Veterinary business.industry Anti-Inflammatory Agents Non-Steroidal Lameness ratio Correction Grapiprant 04 agricultural and veterinary sciences General Medicine medicine.disease Arthritis Experimental Uric Acid Sulfonylurea Compounds chemistry Lameness lcsh:SF600-1100 business Research Article
Zdroj:	BMC Veterinary Research, Vol 15, Iss 1, Pp 1-9 (2019) BMC Veterinary Research
ISSN:	1746-6148
Popis:	Background Non-steroidal anti-inflammatory drugs (NSAIDs) are an important tool in the management of canine osteoarthritis, with the most recent introduction into the category being grapiprant, a piprant that selectively targets the EP4 prostaglandin receptor. To date there have been no efficacy studies comparing grapiprant with other NSAIDs. A randomized, two-sequence, assessor-blinded study involving two separate experiments was undertaken to measure the potency and persistence of acute pain control over 24 h resulting from a single oral dose of either firocoxib (Previcox®) or grapiprant (Galliprant®) in an acute arthritis model. Results Force-plate derived lameness ratios (0, no force recorded on the plate; 1, normal force) for the untreated group remained at 0 for most post-arthritis induction (PAI) assessments in both experiments. Throughout Experiment 1, mean PAI lameness ratios of the firocoxib-treated group remained at or above 0.80. In the grapiprant-treated group, ratios were 0 at 5 and 7 h PAI (7 and 9 h post-treatment), and 0.16 at 10 h PAI (12 h post-treatment). For lameness ratios, relative to the firocoxib group, the control and grapiprant group ratios were significantly lower at each PAI assessment (p ≤ 0.026 and p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bbcd5339c0be0c5516d35410792a5cd http://link.springer.com/article/10.1186/s12917-019-2052-0 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.